“We are pleased to have licensed this technology platform from Kalium as it enables Urigen to develop important and innovative treatments for the urology medical community,” said William Garner, president and CEO of Urigen.
“This license agreement demonstrates Urigen's commitment to be a leader in developing treatments for unmet and/or underserved urological indications,” he continued.
Urigen has five products in development for urology indications that are either in or positioned to enter phase II clinical trials. The pipeline includes U101, for which a phase IIb study for the treatment of chronic pelvic pain (CPP) is ongoing; U102, targeting symptoms of CPP secondary to pelvic irradiation; U103, targeting dyspareunia; U301, targeting acute urethral discomfort (AUD); and U302, targeting urethritis. Of these treatments, U301 is already using the licensed technology platform.